Format:
16
ISSN:
1879-0461
Content:
Owing to the introduction of next-generation sequencing (NGS) new challenges for diagnostic algorithms and the interpretation of the results for therapeutic decision making in hemato-oncology have arisen. Recurrent somatic mutations crossing the borders between different hematological entities and solid neoplasms have been detected. In analogy to mutant TP53, the same mutation type may occur in myeloid, B- or T-lymphatic malignancies or solid neoplasms. At the same time, a certain mutation can show different prognostic outcomes in different entities and co-existence of certain mutations may change the prognostic relevance. These insights may spark the investigation of targeted therapies with the same substances across different disease entities. This review article summarizes mutations that can emerge in different hematologic and solid malignancies and summarizes other obstacles in the era of modern molecular diagnostics, such as the phenomenon of "clonal hematopoiesis of indeterminate potential" being difficult to interpret in the individual patient.
Note:
Gesehen am 19.09.2019
In:
Critical reviews in oncology, hematology, Amsterdam [u.a.] : Elsevier Science, 1983, 126(2018), Seite 64-79, 1879-0461
In:
volume:126
In:
year:2018
In:
pages:64-79
In:
extent:16
Language:
English
DOI:
10.1016/j.critrevonc.2018.03.020